Clinical Trial Update: ACTengine® IMA203 Combined With mRNA-4203 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update indicating ACTengine IMA203 in combination with mRNA-4203 is in early-stage testing for melanoma of the skin and synovial sarcoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma of the Skin
• Synovial Sarcoma

Drugs mentioned

• ACTengine IMA203 (IMA203)
• mRNA-4203 (mRNA-4203)

Snippet

Sponsor: Immatics US, Inc. | Conditions: Cutaneous Melanoma, Synovial Sarcoma | Phase 1 | Status: RECRUITING